tbuckley/cabot-search huggingface dataset:
Analysis of membrane metallopeptidases NEPand ECE expression in prostate cancer tissue microarrays
Authors: Badar A. Usmani, Emma J. Leah, Philip Quirke, Anthony J. Turner
Journal: Cancer Research (2005)

3167   Prostate Cancer (PC) cells which survive androgen withdrawal therapy can switch allegiance to alternative growth pathways, fuelled by mitogenic peptides, which are normally inactivated by zinc metalloproteinases belonging to a small family of Neprilysin (NEP)-like enzymes. In human PC, NEP loss is recognised as contributing to metastatic androgen-independent PC progression by allowing mitogenic peptides such as endothelin-1 (ET-1) to stimulate cell proliferation. ECE-1, a close homologue of NEP, generates active endothelin (ET-1). We have shown that highly metastatic, androgen-independent PC cell lines express high levels of ECE-1 whereas little ECE-1 is seen in poorly metastatic, androgen-sensitive LNCaP cells. We have also shown a tight inverse correlation between PC expression of NEP and ECE-1. In this study, analysis of archive patient PC tissue microarrays revealed 54% high grade and 19% low grade patient tumours expressed ECE, whereas 15% high grade and 25% low grade tumours expressed NEP. ECE-1 is recognised to exist as four isoforms a,b,c,d. ECE-1c appears to be the common isoform present on cell membranes both in epithellia and stroma of highly malignant tumours. On the other hand, ECE-1a has been unexpectedly recognised in the nucleus of malignant cells and the significance of this remains to be explored. Interestingly, TMA cores representing benign prostatic hyperplasia (BPH) revealed mainly NEP expression (81%). Conclusion: the data presented here shows an inverse correlation between NEP and ECE-1 in prostate TMA’s. This data needs to be correlated with remaining clinical evidence, such as PSA levels, Gleason score, AR status etc, in order to identify a value for ECE and NEP as prognostic or therapeutic markers for prostate cancer.
Risk of end‐stage liver disease, hepatocellular carcinoma, and liver‐related death by fibrosis stage in the hepatitis C Alaska Cohort
Authors: Dana J.T. Bruden, Brian J. McMahon, Lisa Townshend‐Bulson, Prabhu Gounder, Jim Gove, Julia Plotnik, Chriss Homan, Annette Hewitt, Youssef Barbour, Philip R. Spradling, Brenna C. Simons, Susan McArdle, Michael Bruce
Journal: Hepatology (2017)

Long‐term prospective studies of the outcomes associated with hepatitis C virus (HCV) infection are rare and critical for assessing the potential impact of HCV treatment. Using liver biopsy as a starting point, we analyzed the development of end‐stage liver disease (ESLD), hepatocellular carcinoma (HCC), and liver‐related death (LRD) according to fibrosis stage among a cohort of American Indian/Alaska Native persons in Alaska. Persons were classified as having no/mild (Ishak = 0,1), moderate (Ishak = 2), or severe (Ishak = 3,4) fibrosis or cirrhosis (Ishak = 5,6). We examined time until development of ESLD, HCC, and LRD and report survival probabilities at 3, 5, 7, and 10 years. Of 407 persons, 39% (n = 150) had no/mild fibrosis, 32% (n = 131) had moderate fibrosis, 22% (n = 88) had severe fibrosis, and 9% (n = 38) had cirrhosis. The average time of follow‐up was 7.3 years. Within 5 years of biopsy, 1.7% (95% confidence interval [CI]: 0.4‐6.8) of persons with no/mild fibrosis developed ESLD compared with 7.9% (95% CI, 4.0‐15.2), 16.4% (95% CI, 9.6‐27.2), and 49.0% (95% CI, 33.0‐67.7) with moderate, severe fibrosis, and cirrhosis, respectively ( P &lt; 0.01). The 5‐year outcome of HCC was 1.0% (95% CI, 0.1‐7.0), 1.0% (95% CI, 0.1‐6.6), 1.1% (95% CI, 0.2‐7.7), and 13.4% (95% CI, 4.4‐36.7) among persons with no/mild fibrosis, moderate fibrosis, severe fibrosis, and cirrhosis, respectively ( P &lt; 0.01). Five years after biopsy, 0.0% (95% CI, 0.0‐14.8) of persons with no/mild fibrosis had suffered an LRD compared with 1.0% (95% CI, 0.2‐7.5) of persons with moderate fibrosis, 4.7% (95% CI, 1.5‐14.1) with severe fibrosis, and 16.3% (95% CI, 7.0‐35.1) with cirrhosis ( P &lt; 0.01). Conclusion : For prevention of HCC, LRD, and ESLD in the short term, HCV therapy should target individuals who have more than mild fibrosis. (H epatology 2017;66:37–45).
Correlation of Pharmacokinetic Data with Cytogenetic and Molecular Response in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib - An Analysis of IRIS Study Data.
Authors: Richard A. Larson, Brian J. Druker, Francois Guilhot, Stephen G. O’Brien, Insa Gathmann, Gilles J. Riviere, Charlene So, Yanfeng Wang
Journal: Blood (2006)
P16.01 Duloxetine in chemotherapy-induced peripheral neuropathy: experience beyond the clinical trial.
Authors: R. Velasco, S. Besora, C. Santos, R. Sala, C. Izquierdo, M. Simó, M. Gil, B. Pardo, E. Domingo, J. Bruna
Journal: Neuro-Oncology (2016)

mandibular dystonia.Due to the various clinical presentations of paraneoplastic neurological syndromes also unusual combinations of neurological signs and symptoms should be considered as potentially paraneoplastic in the diagnostic workup.
Lung cancer patients and unplanned presentations to hospital: insights from a single institution experience
Authors: V. Buoro, E. De Carlo, L. Gerratana, M. Giavarra, S. Rizzato, C. Rossetto, M. Macerelli, E. Poletto, M. Cattaneo, G. Pelizzari, M. Mansutti, G. Aprile, A. Follador, F. Puglisi, G. Fasola
Journal: Annals of Oncology (2016)
Lower risk of cutaneous squamous cell carcinomas induced by vemurafenib in non melanoma patients
Authors: E. Maubec, A. Levy, C. Cropet, J. Mazieres, X. Troussard, S. Leboulleux, D. Malka, M. Dinulescu, F. Granel-Brocard, D. Le Goupil, F. Truchetet, S. Dalle, M.T. Leccia, N. Hoog-Labouret, C. Mahier Ait Oukhatar, B. Busser, J. Charles, J.-Y. Blay
Journal: Annals of Oncology (2016)
KRAS mutations in circulating tumour DNA (ctDNA) in MRI-defined, high-risk, locally-advanced rectal cancer (LARC) patients (pts) from the EXPERT-C trial
Authors: F. Sclafani, I. Chau, D. Cunningham, G. Vlachogiannis, Z. Eltahir, A. Lampis, C. Braconi, E. Kalaitzaki, D. Gonzalez De Castro, A. Wotherspoon, J. Capdevila, B. Glimelius, A. Cervantes, R. Begum, H. Lote, G. Mentrasti, J.C. Hahne, D. Tait, G. Brown, N. Valeri
Journal: Annals of Oncology (2016)
Complete resection rate at interval debulking surgery after bevacizumab containing neoadjuvant therapy: primary objective of the ANTHALYA trial
Authors: R. Rouzier, S. Gouy, F. Selle, E. Lambaudie, F. Guyon, V. Fourchotte, C. Pomel, P.-E. Colombo, E. Kalbacher, S. Martin-Francoise, R. Fauvet, P. Follana, A. Lesoin, F. Lecuru, Y. Ghazi, J. Dupin, E. Chereau, S. Zohar, P. Cottu, F. Joly
Journal: Annals of Oncology (2016)
Pharmacokinetics and Response to Treatment Using a Combination of Fludarabine and Alemtuzumab (FluCam) in Patients with Relapsed/Refractory CLL.
Authors: T. Elter, J. Kilp, T. Piironen, P. Borchmann, H. Schulz, J. Bohlius, Michael J. Hallek, Andreas Engert
Journal: Blood (2006)
Inhibition of serotonin receptor type 1 in acute myeloid leukemia impairs leukemia stem cell functionality: a promising novel therapeutic target
Authors: A Etxabe, M C Lara-Castillo, J M Cornet-Masana, A Banús-Mulet, M Nomdedeu, M A Torrente, M Pratcorona, M Díaz-Beyá, J Esteve, R M Risueño
Journal: Leukemia (2017)
RARE-57. GIANT INTRAOSSEOUS HEMANGIOMA OF THE PETROUS BONE: A CASE REPORT AND LITERATURE REVIEW
Authors: Juanita Garces, Mansour Mathkour, Cuong J. Bui, Olawale A.R. Sulaiman, Marcus Ware
Journal: Neuro-Oncology (2016)

Intraosseous hemangiomas are rare entities that make up approximately 1% of primary bone tumors and are most commonly located in the vertebrae or calvaria. Hemangiomas of the skull base are extremely rare and are most frequently located in the petrous portion of the temporal bone. We present a case of the largest intraosseous hemangioma in the temporal bone reported. The patient is a 62-year-old male who presented with complaints of right-sided headaches and facial droop. Physical examination was abnormal only for the right-sided facial droop. MRI showed a mass along the superior aspect of the right petrous temporal bone measuring approximately 5.3x4.7x4.5 cm causing brainstem compression. Angiography defined a blood supply from branches originating in the internal carotid artery and showed contrast pooling in vascular spaces of the mass. Embolization was not done pre-operatively due to the proximity of the tumor vasculature to the internal carotid artery. The patient underwent a craniotomy for complete resection of the infratentorial tumor. Postoperative imaging showed complete resection of the mass. Pathology confirmed that mass was a hemangioma. It has been 4 years since the patient’s initial presentation with no recurrence. Few cases have been reported in the literature of temporal hemangioma, herein we present the largest intraosseous hemangioma located in the apex of petrous bone of the skull base causing brainstem compression. This case illustrates the diversity of proliferating cell masses and suggests that the growth of these masses and size may not necessarily be localized to conventional areas.
MPTH-56. ALGORITHM BASED LIQUID BIOPSY FOR THE DIAGNOSIS OF GLIOBLASTOMA
Authors: Amit Ray, Dadasaheb Akolkar
Journal: Neuro-Oncology (2016)

The aim of this study was to develop an algorithm that would accurately diagnose, offer therapy management options and help in the monitoring of recurrence in patients with glioblastoma. In a prospective study, after ethics committee approval, ninety samples and fifty controls were collected from Apollo Hospitals. All patients had lesions that had the radiological appearance of a high grade glioma. All patients had attempted radical resections. Blood samples were drawn after written consent either on the day or on the day before surgery. Pathological diagnosis was considered to be the gold standard. Liquid biopsy was performed using the 'Next Gen Sequencing' platform. Analysis was based on the data obtained from analysis of exosomal RNA, cell free DNA and micro RNA. The lab was blinded to the results of the biopsy till the entire study was completed. Big data analysis revealed 19 different markers that can help in the diagnosis, pathway analysis and recurrence monitoring of glioblastoma. This included EGFR amplification, PDGFR amplification, NF1 mutation, TP53 mutation, PTEN mutation etc and microRNAs miR-27a, 210, 124, 210 etc. 48 tumors were diagnosed to be GBMs by the pathologists. All 48 were diagnosed on liquid biopsy as well. 27 tumors were diagnosed as grade 3. Liquid biopsy identified 24 as grade 3 and 3 as GBMs. The rest were Grade 2 according to pathology. Of these, there were 15 tumors. However, 3 were classified as GBMs and 4 were thought to be grade 3 tumors. All control samples were negative. Liquid biopsy can play an important role in the diagnosis of patients with gliomas and reduce the under reporting of high grade gliomas caused by tumor heterogeneity.
Clinical Significance and Pathopysiological Function of the Tim-3/Galection-9 Pathway in Myelodysplastic Syndromes
Authors: Toshio Asayama, Mariko Ishibashi, Hideto Tamura, Yasuko Hamada, Namiko Okuyama, Asaka Onodera, Akiko Yamada, Keiichi Moriya, Norio Yokose, Koiti Inokuchi
Journal: Blood (2015)
DRES-04. TUMOR HETEROGENEITY CONTRIBUTES TO RESISTANCE TO ANTI-EGFR THERAPY IN GLIOBLASTOMA
Authors: Ciro Zanca, Frank Furnari
Journal: Neuro-Oncology (2016)

Glioblastoma is the most aggressive tumor type affecting the adult brain, with an overall patient survival from the time of diagnosis of about 15 months. Tumor promoting proteins such as EGFR (Epidermal Growth Factor Receptor) and its mutant form, EGFRvIII, are amplified in a subgroup of patients and have attracted attention as potential therapeutic targets. Unfortunately, kinase inhibition of EGFR or EGFRvIII has been proven to be ineffective due to resistance mechanisms that prevent the onset of cell death. We found that the presence of cytokines in the tumor microenvironment, induced by inter-clonal communication between heterogeneous tumor cell populations expressing EGFRvIII and EGFR, in addition to their previously shown promotion of glioblastoma growth, also promote resistance to EGFR-directed therapies. To identify the mechanism mediating resistance, we interrogated core pathways known to protect cancer cells from induced cell death. Results show that EGFRvIII cells expressing interleukin-6 (IL-6) promote paracrine activation of NF-kB in EGFR cells and subsequent expression of a NF-kB target gene, survivin (BIRC5), known to block cell death by attenuating caspase 3/7 activation. Demonstrating a causal link of cytokine signaling and EGFR TKIs resistance, pharmacological inhibition of NF-kB or knockdown of survivin restored sensitivity to gefitinib, erlotinib or lapatinib, both in vitro and in in vivo models of EGFR/EGFRvIII heterogeneous tumor growth. These results illustrate a novel treatment approach to enhance EGFR inhibition by uncoupling the effect of a paracrine-mediated survival pathway established by heterogeneous tumor growth.
STMC-39. PRECISION FUNCTIONAL GENOMICS FOR GLIOBLASTOMA: IDENTIFYING MOLECULAR THERAPEUTIC TARGETS USING CRISPR-Cas9 AND RNAi TECHNOLOGIES DIRECTLY IN TUMOR ISOLATES
Authors: Pia Hoellerbauer, Heather Feldman
Journal: Neuro-Oncology (2016)

Glioblastoma (GBM) is the most aggressive and common form of adult brain cancer and is among the deadliest cancers, with a median survival of 15 months using standard-of-care therapies. Thus, improved treatments for GBM are desperately needed. To identify new GBM molecular therapeutic targets, our group has performed multiple functional genetic screens in patient-derived GBM stem-like cells (GSCs) and non-transformed human neural stem and progenitor cells (NPCs), which represent non-neoplastic controls. These screens, using both RNAi and CRISPR-Cas9 platforms, have led to the identification of several key molecular vulnerabilities in GSCs, including GBM-specific defects in: 3’ splice site recognition, kinetochore function, and PKMYT1 and WEE1 activity. At this meeting, we will present an overview of these studies as well as our current efforts to: comprehensively retest all GBM-specific vulnerabilities scoring in these screens; address whether vulnerabilities arise from specific genetic alterations in patient tumors (e.g., PIK3CA activation vs. PTEN loss); determine whether inhibition of specific molecular targets blocks tumor growth and/or maintenance; and demonstrate the mode of GBM-specific death for particular targets (e.g., cell cycle arrest, apoptosis, etc). In addition, we will highlight both strengths and weaknesses of applications of CRISPR-Cas9 technologies in patient samples. Collectively, our work illustrates the power of combining functional genetic technologies with the use of tumor-derived cells to identify novel, patient-specific therapeutic strategies for GBM.
Intra-tumor heterogeneity from a cancer stem cell perspective
Authors: Pramudita R. Prasetyanti, Jan Paul Medema
Journal: Molecular Cancer (2017)

Tumor heterogeneity represents an ongoing challenge in the field of cancer therapy. Heterogeneity is evident between cancers from different patients (inter-tumor heterogeneity) and within a single tumor (intra-tumor heterogeneity). The latter includes phenotypic diversity such as cell surface markers, (epi)genetic abnormality, growth rate, apoptosis and other hallmarks of cancer that eventually drive disease progression and treatment failure. Cancer stem cells (CSCs) have been put forward to be one of the determining factors that contribute to intra-tumor heterogeneity. However, recent findings have shown that the stem-like state in a given tumor cell is a plastic quality. A corollary to this view is that stemness traits can be acquired via (epi)genetic modification and/or interaction with the tumor microenvironment (TME). Here we discuss factors contributing to this CSC heterogeneity and the potential implications for cancer therapy.
Submucosal tunneling endoscopic resection (STER) with full-thickness muscle excision for a recurrent para-aortic esophageal leiomyoma after surgery
Authors: Gianfranco Donatelli, David Fuks, Guillaume Pourcher, Isabelle Dumontier, Fabrizio Cereatti, Thierry Perniceni, Brice Gayet
Journal: Endoscopy (2017)

We report the case of a 49-year-old woman with a recurrent esophageal leiomyoma following two surgical resections. The surgical procedures had been performed 23 and 21 years previously. Follow-up showed lesion recurrence in the mid esophagus ([Fig. 1] and [Fig. 2]).
Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
Authors: J.J. Park, S. Parakh, S. Mendis, R. Rai, S. Lo, A. Haydon, M.C. Andrews, J. Cebon, A. Guminski, R. Kefford, G.V. Long, A.M. Menzies, O. Klein, M.S. Carlino
Journal: Annals of Oncology (2016)
Neo/adjuvant ADT to EBRT: Randomized phase 2 trial of the oral GnRH antagonist, TAK-385 (relugolix, RGX) and degarelix (DGX) in patients (pts) with prostate cancer (PC)
Authors: D. Dearnaley, D.R. Saltzstein, J.E. Sylvester, L. Karsh, B.A. Mehlhaff, C. Pieczonka, J.L. Bailen, D.B. Maclean, S. Sankoh, H.M. Faessel, H.M. Lin, N.D. Shore
Journal: Annals of Oncology (2016)
Erratum: BAC Consensus Conference, November 4-6, 2004: Epidemiology, pathogenesis, and preclinical models (Journal of Thoracic Oncology (2006) 1, (S2-S7))
Authors: D. C. Christiani, W. Pao, J. C. DeMartini, R. I. Linnoila, A. M. Malkinson, Amir Onn, K. A. Politi, M. Sharp, K. K. Wong
Journal: Journal of Thoracic Oncology (2007)
Haploidentical Transplantation In Adults ≥ 66 Years of Age
Authors: Dolores Grosso, Onder Alpdogan, Emmanuel C. Besa, Matthew Carabasi, Beth Colombe, Patricia Cornett Farley, Joanne Filicko-O'Hara, Elena Gitelson, Margaret Kasner, Ubaldo Martinez-Outshoorn, William O'Hara, John L. Wagner, Mark Weiss, Neal Flomenberg
Journal: Blood (2010)
A phase 1b/2 dose escalation and cohort expansion study of the safety, tolerability and efficacy of a transforming growth factor-beta (TGF-&amp;bgr;) receptor I kinase inhibitor (galunisertib) in combination with anti–PD-1 (nivolumab) in advanced refractory solid tumours
Authors: S.C. Guba, S. Mukhopadhyay, D. Desaiah, V.A.M. Andre
Journal: Annals of Oncology (2016)
Epigenomics of human CD8 T cell differentiation and aging
Authors: David M. Moskowitz, David W. Zhang, Bin Hu, Sabine Le Saux, Rolando E. Yanes, Zhongde Ye, Jason D. Buenrostro, Cornelia M. Weyand, William J. Greenleaf, Jörg J. Goronzy
Journal: Science Immunology (2017)

Genome-wide epigenetic profiling defines the transcriptional networks involved in T cell aging.
Safety and efficacy of new techniques of radiotherapy in oligometastatic recurrence ovarian cancer ( ROC) patients with BRCA 1/2 mutation. A monoistitutional experience
Authors: G. Scandurra, F. Marletta, S. Nicolini, G.L. Banna, A.B. Di Stefano, S. Cali', G. Acquaviva, M. Tamburo, G. Corsaro, G. Scibilia, M. Ippolito, P. Scollo
Journal: Annals of Oncology (2016)
Fludarabine Monophosphate in Indolent Non Hodgkin’s Lymphoma (NHL) - Clinical Experience (1995–2006).
Authors: J.E. Novoa, B. Beñaran, A.L. Rojo, R. Draper, H. Calvo, N. Iriondo, L. Diaz, M. Rivero, J. Segura, P. Segura, A. Sosa, S. Brignoni, A. Luongo, R. De Bellis
Journal: Blood (2006)
Effect of Donor on Outcomes after Myeloablative Conditioning with Daily IV Busulfan and Fludarabine (FLUBUP) +/− TBI with Thymoglobulin: Transplants from Mismatched Unrelated Donors (MMUD) Have Worse Survival Due to Higher Transplant-Related Mortality (TRM).
Authors: James A. Russell, Leanne Kmet, Mary Lynn Savoie, Nizar J. Bahlis, M. Ahsan Chaudhry, Diana M. Quinlan, Michelle Geddes, A. Robert Turner, Loree M. Larratt, Christopher Brown, Jan Storek, Douglas A. Stewart
Journal: Blood (2006)
PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis
Authors: G.V. Long, J. Larkin, P.A. Ascierto, F.S. Hodi, P. Rutkowski, V. Sileni, J. Hassel, C. Lebbe, A.C. Pavlick, J. Wagstaff, D. Schadendorf, R. Dummer, D. Hogg, J.B.A.G. Haanen, P. Corrie, C. Hoeller, C. Horak, J. Wolchok, C. Robert
Journal: Annals of Oncology (2016)
KEYNOTE-183: A randomized, open-label phase 3 study of pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma
Authors: M.V. Mateos, H. Blacklock, A.O. Rocafiguera, S. Iida, S. Jagannath, S. Lonial, U. Kher, M. Farooqui, P. Marinello, J. San-Miguel
Journal: Annals of Oncology (2016)
Impact of primary tumour resection on survival and chemotherapy tolerance in patients with metastatic oesophagogastric cancer undergoing palliative chemotherapy
Authors: S. Ochenduszko, M. Puskulluoglu, K. Konopka, A. Michalowska-Kaczmarczyk, K. Fijorek, M. Pedziwiatr, A. Budzynski
Journal: Annals of Oncology (2016)
Neutrophil Extracellular Traps in Atherosclerosis and Atherothrombosis
Authors: Yvonne Döring, Oliver Soehnlein, Christian Weber
Journal: Circulation Research (2017)

Neutrophil extracellular traps expelled from suicidal neutrophils comprise a complex structure of nuclear chromatin and proteins of nuclear, granular, and cytosolic origin. These net-like structures have also been detected in atherosclerotic lesions and arterial thrombi in humans and mice. Functionally, neutrophil extracellular traps have been shown to induce activation of endothelial cells, antigen-presenting cells, and platelets, resulting in a proinflammatory immune response. Overall, this suggests that they are not only present in plaques and thrombi but also they may play a causative role in triggering atherosclerotic plaque formation and arterial thrombosis. This review will focus on current findings of the involvement of neutrophil extracellular traps in atherogenesis and atherothrombosis.
SURG-17. GROSS TOTAL RESECTION OUTCOMES IN ADULT PATIENTS WITH BRAINSTEM GLIOMA
Authors: Kailin Yang, Leo Kim, John Suh, Erin Murphy, Samuel Chao
Journal: Neuro-Oncology (2016)

Brainstem glioma (BSG) is much more rare and heterogeneous in adults compared to pediatric population. Clinical outcome of this type of brain tumor remains poor despite aggressive treatment. We analyzed 1667 patients of age 19 or older with the diagnosis of BSG identified from the NCI Surveillance, Epidemiology, and End Results database (1973-2012). Surgical treatment was categorized into no surgery, subtotal resection (STR), and gross total resection (GTR). Kaplan-Meier analysis and multivariate Cox proportional hazard modeling were used to assess the impact of treatment on overall survival (OS). 54.6% were males, and 83.1% were Caucasian. The median age was 45.5 years. Surgery was only performed in a small subset of patients with 7.4% receiving STR and 6.4% receiving GTR. OS at 10 years was 26.8%, with a median follow-up time of 9.7 years. Advanced age and high WHO grade were associated with poor OS, with 8.9% for age 75+ and 10.3% for grade IV at 10 years respectively. There was no significant OS benefit with RT for grade III (18.9% with RT vs. 18.4% without RT, p=0.94), but improved OS with RT for grade IV (12.1% with RT vs. 3.39% without RT, p=0.03). However, worse OS was observed with RT for grade I and grade II. Multivariate analysis adjusting for age, gender, year of diagnosis and WHO grade revealed improved OS associated with GTR (HR 0.574, 95% CI 0.412-0.777, p<0.01). The overall outcome of high-grade adult BSG remains poor though RT provides benefit on OS for grade IV tumors, keeping in mind possible bias in offering RT to patients with worse prognosis. GTR is associated with improved survival in a subset of patients. Given the unfavorable survival of high-grade BSG, more specific therapeutic regimen targeting the underlying genetic aberration is needed to improve patient outcome.
Mechanism of Suppression Effect of Myeloid-Derived Suppressor Cells on Hyperacute Graft-Versus-Host Disease
Authors: Yigeng Cao, Ming-Zhe Han, Peng Liu, Haiyan Gong, Haiyan Zhu, Sizhou Feng, Hongbo R. Luo, Yuanfu Xu
Journal: Blood (2016)